Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P662: Remission to vedolizumab is not higher in TNF-naïve compared with TNF-pre-treated patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Biedermann1, O. Mader2, P. Hruz3, P. Juillerat4, P. Michetti5, V. Pittet5, G. Rogler1, F. Seibold*2

1UniversitätsSpital Zürich, Zürich, Switzerland, 2Crohn Colitis Zentrum Bern, Bern, Switzerland, 3Universitätsspital Basel, Basel, Switzerland, 4Universitätsklinik Inselspital, Bern, Switzerland, 5Université de Lausanne, Lausanne, Switzerland

P663: The effect of vitamin D deficiency, and its correction, on healthcare utilisation among patients with inflammatory bowel disease (IBD)

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Chou1, J. Gubatan2, O. H. Nielsen3, A. Moss*1

1Beth Israel Deaconess Medical Center, Gastroenterology, Boston, USA, 2Stanford University Medical Center, Gastroenterology, Stanford, USA, 3University of Copenhagen, Clinical Medicine, Copenhagen, Denmark

P664: SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Gonçalves*1, G. Myung2, E. Hong2, M. Park2, D. Jeong2, J. Ghil2

1Faculdade Farmacia Universidade Lisboa, iMed - Research Institute for Medicines, Lisboa, Portugal, 2Samsung Bioeips Co., Ltd., Incheon, South Korea

P665: 1-Year clinical and endoscopic follow-up of vedolizumab therapy in refractory PIBD patients

ECCO '19 Copenhagen

Year: 2019
Authors:

M. M. E. Jongsma*1, M. A. Aardoom1, L. de Ridder1, J. C. Escher1

1Erasmus Medical Center - Sophia Children's Hospital, Paediatric gastroenterology, Rotterdam, The Netherlands

P666: Safety of combination biologic and immunosuppressive therapy post-orthotopic liver transplantation in patients with inflammatory bowel disease: a systematic review

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Al Draiweesh*1,2, C. Ma1,3, M. Alkhattabi1,4, T. Nguyen5, M. Brahmania1, V. Jairath1,6

1Western University, Department of Medicine, Division of Gastroenterology, London, Ontario, Canada, 2King Fahad Specialist Hospital, Department of Medicine, Division of Gastroenterology, Dammam, Saudi Arabia, 3University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Alberta, Canada, 4King Abdulaziz University, Department of Medicine, Rabigh, Saudi Arabia, 5Robarts Clinical Trials, Inc., London, Ontario, Canada, 6Western University, Department of Epidemiology and Biostatistics, London, Ontario, Canada

P667: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates in 72 patients, a report from a district general hospital

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Radhakrishnan*1, H. Johnson1, K. Wade1, S. McLaughlin1

1Royal Bournemouth Hospital, Gastroenterology, Bournemouth, UK

P668: Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Rullan1, A. Elosua*1, C. Saldaña1, E. Amorena1, M. Vicuña1, S. Rubio1, Ó. Nantes1, C. Rodríguez1

1Complejo Hospitalario de Navarra, Gastroenterology and Hepatology, Pamplona, Spain

P669: Transmural healing is associated with higher infliximab trough levels in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Albshesh1, B. Unger1,2, S. Ben Horin2, R. Eliakim2, U. Kopylov2, D. Carter*2

1Chaim Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 2Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel

P670: Therapeutic efficacy and economic impact of half sulfasalazine therapy for refractory ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Kunisaki*1, M. Tatsuno1, J. Kouyama1, C. Kawamoto1, H. Nishioka1, A. Mizoguchi1, Y. Nakamori1, T. Mitsui1, K. Chida1, Y. Hashimoto1, Y. Tamura1, A. Ikeda1, T. Ogashiwa1, R. Suzuki2, S. Maeda3, H. Kimura1

1Yokohama City University Medical Center, Inflammatory Bowel Disease Center, Yokohama, Japan, 2Kannai Suzuki Clinic, Yokohama, Japan, 3Yokohama City University Graduate School of Medicine, Department of Gastroenterology, Yokohama, Japan

P671: Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study

ECCO '19 Copenhagen

Year: 2019
Authors:

J. R. White1,2,3, S. Din3, R. Ingram4, S. Foley4, M. A. Alam5, R. Robinson5, R. Francis2, E. Tucker2, M. Jalal6, D. Elphick6, E. Atallah1,7, A. Norman7, M. Amin8, A. Sajjad8, N. Heggs9, S. Meadowcroft9, G. Moran*1,2

1NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK, 2Nottingham Digestive Diseases Centre, The University of Nottingham, Nottingham, UK, 3University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, UK, 4Sherwood Forest Hospitals NHS Foundation Trust, Kings Mill Hospital, Nottingham, UK, 5University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK, 6Chesterfield Royal Hospital NHS Foundation Trust, Chesterfield, UK, 7United Lincolnshire Hospitals NHS Trust, Lincoln County Hospital, Lincoln, UK, 8Kettering General Hospital NHS Foundation Trust, Kettering, UK, 9Takeda UK Ltd., High Wycombe, UK

P672: Drug therapy and monitoring for inflammatory bowel diseases: preliminary data from a multi-centre investigation in Asia

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Cai1, J. Shen1, J. Tong1, J. Lu1, Q. Zheng1, K. Wu2, J. Qian3, Z. Ran*1

1Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Shanghai Institute of Digestive Disease; Shanghai Inflammatory Bowel Disease Research Center, Shanghai, China, 2Department of Gastroenterology, Xijing Hospital, Air Force Military Medical University, Xi'an, China, 3Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China

P673: Achievement of tight control based on serum C-reactive protein and albumin correlated with better outcomes in Japanese Crohn’s disease patients treated with biologics

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Shiga*1, I. Abe1, M. Onodera1, R. Moroi1, M. Kuroha1, Y. Kanazawa1, Y. Kakuta1, Y. Kinouchi1,2, A. Masamune1

1Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan, 2Tohoku University, Health Administration Center, Center for the Advancement of Higher Education, Sendai, Japan

P674: Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Szántó1, A. L. Szíjártó2, D. Kata3, I. Földesi3, Z. A. Mezei4, A. Fábián1, A. Bálint1, R. Bor1, K. Farkas1, Á. Milassin1, M. Rutka1, Z. Szepes1, F. Nagy1, T. Bubán5, S. Lovas6, K. Palatka6, T. Molnár1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 3University of Szeged, Institute of Laboratory Medicine, Szeged, Hungary, 4University of Debrecen, Department of Laboratory Medicine, Debrecen, Hungary, 5University of Debrecen, Department of Internal Medicine, Debrecen, Hungary, 6University of Szeged, 2nd Department of Internal Medicine, Debrecen, Hungary

P675: The relationship between gender, severity of disease, treatment type, and employment outcome in patients with inflammatory bowel disease in Israel

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Naftali*1,2, A. Ein Dor Abarbanel3, N. Ruhimovich2, A. Bar-Gil Shitrit4, F. Sklerovsky-Benjaminov1,2, H. Shirin1,3, S. Matalon1,3, T. Ziv Baran5, E. Broide1,3

1Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel, 2Meir Hospital, Gastroenterology and Liver disease, Kfar Saba, Israel, 3Assaf Harofeh, The Kamila Gonczarowski Institute for Gastroenterology and Liver Diseases, Zerifin, Israel, 4Shaare Zedek Medical Center, Gastroenterology institute, Jerusalem, Israel, 5Sackler Faculty of Medicine Tel Aviv University, Department of Epidemiology and Preventive Medicine, Tel aviv, Israel

P676: The impact to disease activity, iron and vitamin D deficiency on fatigue in IBD patients

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Atanassova*1, A. Georgieva1, D. Gerova2, M. Todorova2

1Medical University Varna, Clinic of Hepatogastroenterology, St. Marina University Hospital, Varna, Bulgaria, 2Medical University Varna, Department of General Medicine and Clinical Laboratory, Varna, Bulgaria

P677: Effect of late faecal loss of infliximab on treatment response of inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

F. AlborziAvanaki*1, H. Rezvan1, N. Ebrahimi Daryani1, N. Ale Taha1

1Tehran university ofMedical Sciences, Tehran, Iran, Islamic Republic of

P678: Treatment of moderate to severe UC patients with new 5ASA tablets

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Laoun*1, R. Hofmann2

1Tillotts Pharma AG, Medical Affairs, Rheinfelden, Switzerland, 2Tillotts Pharma, Medicines Management, Rheinfelden, Switzerland

P679: Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Schreiber*1, S. Ben-Horin2, B. D. Ye3, R. Westhovens4, D. H. Yoo5, S. J. Lee6, J. H. Suh6, J. H. Byeon6, W. Reinisch7

1University Hospital Schleswig-Holstein, Kiel, Germany, 2Sheba Medical Center, Tel Hashomer, Israel, 3Asan Medical Center, Seoul, South Korea, 4University Hospital KU Leuven, Leuven, Belgium, 5Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 6Celltrion, Inc., Incheon, South Korea, 7Medical University Vienna, Vienna, Austria

P680: Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Ghosh*1, B. C. Kramer2, C. Gasink2, D. Jacobstein3, O. J. Adedokun3, L-L. Gao3, P. Rutgeerts4, B. E. Sands5

1University of Birmingham, Birmingham, UK, 2Janssen Scientific Affairs, LLC, Horsham, USA, 3Janssen Research and Development, LLC, Spring House, USA, 4University Hospital Gasthuisberg, Leuven, Belgium, 5Icahn School of Medicine at Mount Sinai, New York, USA

P681: Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies

ECCO '19 Copenhagen

Year: 2019
Authors:

B. E. Sands*1, C. Han2, H. Zhang3, J. Johanns3, P. Szapary3, C. Marano3, R. W. Leong4,5, S. Danese6

1Icahn School of Medicine at Mount Sinai, New York, USA, 2Janssen Global Services, LLC, Malvern, USA, 3Janssen Research & Development, LLC, Spring House, USA, 4Concord Hospital, Sydney, Australia, 5Macquarie University Hospital, Sydney, Australia, 6Humanitas Research Hospital, Milan, Italy